The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 1,201–1,300 of 2,716
The impact of mild autonomous cortisol secretion and proposed interventions
Iriarte-Durán, M. B., Donato, S., Herrera-Martínez, A. D., Vega, A., Casinello, J. M. J., Marazuela, M., & Castro, M. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2480704 · Cited by 11
“The Endocrine Society in 2008 [12] suggests the use of highly sensitive tests to screen for hypercortisolism in patients with AIs.”
Sasson, L., Dery, L., Stern, J., Shimon, I., Rudman, Y., Dotan, I., Kushnir, S., Shochat, T., Fleseriu, M., & Akirov, A. (2025) · Pituitary · doi:10.1007/s11102-025-01550-z · Cited by 11
Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT)
Nieman, L. K., Boscaro, M., Scaroni, C. M., Deutschbein, T., Mezősi, E., Driessens, N., Georgescu, C. E., Motyka, M., Hubalewska–Dydejczyk, A., Jarząb, B., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf181 · Cited by 16
Self-citationIdentification of Potential Markers for Cushing Disease
Broder, M. S., Chang, E. Y., Cherepanov, D., Neary, M. P., & Ludlam, W. H. (2016) · Endocrine Practice · doi:10.4158/ep15914.or · Cited by 10
“8% in older patients with osteoporosis and vertebral fractures (9).”
BackgroundValidity of discharge ICD-10 codes in detecting the etiologies of endogenous Cushing’s syndrome
Zhou, J., Zhang, M., Lü, L., Guo, X., Gao, L., Yan, W., Pang, H., Wang, Y., & Xing, B. (2019) · Endocrine Connections · doi:10.1530/ec-19-0312 · Cited by 9
Ferrante, E., Serban, A. L., Clerici, M., Indirli, R., Scalambrino, E., Carosi, G., Padovan, L., Locatelli, M., Arosio, M., Peyvandi, F., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01605-5 · Cited by 11
Common Pitfalls in the Interpretation of Endocrine Tests
Álvarez-Payares, J. C., Bello-Simanca, J. D., Peña-Arrieta, E. D. J. D. L., Agamez-Gomez, J. E., García-Rueda, J. E., Rodriguez-Arrieta, A., & Arrieta, L. A. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.727628 · Cited by 16
Wu, V., Chan, C., Wu, W.-C., Peng, K., Chang, Y.-S., Yeh, F.-Y., Chiang, J., Lee, Y., Liu, K., Wang, S., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-01086-w · Cited by 10
“8 μg/dL was proposed by the European Society of Endocrinology for the diagnosis of ACS [20, 27].”
MethodMartino, M., Aboud, N., Lucchetti, B., Salvio, G., & Arnaldi, G. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192349 · Cited by 10
“The combination of metyrapone and ketoconazole was used successfully and without significant side effects in 14 patients with severe hypercortisolism related to EAS or ACC [122].”
BackgroundInfluentialGarg, R., Memon, S. S., Lila, A. R., Sarathi, V., Patil, P., Jamale, T., Bose, S., Karlekar, M. P., Patil, V. A., Shah, N. S., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae002 · Cited by 12
“The Endocrine Society guidelines suggest using a combination of 24-h UFC, LNSC, and ONDST to screen for CS [3].”
BackgroundMethodSubtyping of Cushing’s Syndrome: A Step Ahead
Tizianel, I., Barbot, M., & Ceccato, F. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2299-5065 · Cited by 12
Truong, H. L., Nellesen, D., Ludlam, W. H., & Neary, M. P. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2013.877470 · Cited by 9
Fukuoka, H. (2015) · Pituitary · doi:10.1007/s11102-015-0637-6 · Cited by 9
“Cushing’s disease (CD) is defined as endogenous hypercortisolemia caused by ACTH-producing pituitary adenomas (ACTHomas), leading to a variety of systemic manifestations, including osteoporosis, infections, psychiatric disorders, muscle atrophy, fat accumulation, hypertension, and hyperglycemia [1, 2].”
BackgroundHypertension artérielle endocrine
Amar, L., Lussey‐Lepoutre, C., Bobrie, G., & Plouin, P. (2010) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2009.08.015 · Cited by 15
Practical Guide to Supportive Care of Patients With Functional Neuroendocrine Tumors
Anthony, L. B. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.11.002 · Cited by 9
Inter-method comparison of salivary cortisol measurement
Baecher, S., Azad, S. C., & Vogeser, M. (2013) · Journal of Laboratory Medicine · doi:10.1515/labmed-2013-0008 · Cited by 12
“Consequently, the use of assay-specific cut-off concentrations is recommended for salivary cortisol assessment in the context of endocrine testing, for example, rule-out of Cushing’s disease [2, 3].”
BackgroundMethodChen, Z., Wang, G., & Jiang, C. (2019) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2019.05.059 · Cited by 11
Pasternak-Pietrzak, K., Moszczyńska, E., & Szalecki, M. (2019) · Endocrine · doi:10.1007/s12020-019-02036-2 · Cited by 11
Sagan, K. P., Andrysiak-Mamos, E., Sagan, L. M., Nowacki, P., Małkowski, B., & Syrenicz, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00460 · Cited by 9
Hagiwara, R., Kageyama, K., Niioka, K., et al. (2020) · Peptides · doi:10.1016/j.peptides.2020.170441 · Cited by 9
Ectopic ACTH production by thymic and appendiceal neuroendocrine tumors – two case reports
Moszczyńska, E., Pasternak-Pietrzak, K., Prokop-Piotrkowska, M., Śliwińska, A., Szymańska, S., & Szalecki, M. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2020-0442 · Cited by 10
“According to the literature, the response to CRH is observed in 5%of patients with EAS, which is linked to the presence of CRH receptors on the tumor cells [5, 7].”
BackgroundApproach to large adrenal tumors
Ambroziak, U. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000631 · Cited by 12
“Two out of three tests should be positive to confirm (CS) [25].”
BackgroundHigh-Risk Pregnancy: Management Options
Wildschut, H. I. J., Duvekot, J. J., Cook, J. R., Bacchus, L. J., Bewley, S., Creighton, S., Dear, J., Williams, D., Kilby, M. D., Crouch, N. S., et al. (2017) · Cambridge University Press eBooks · doi:10.1017/9781108349185 · Cited by 11
Cushing’s syndrome is associated with altered adipokine profile
Dadej, D., Szczepanek‐Parulska, E., Wrotkowska, E., & Ruchała, M. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032329 · Cited by 9
A hyperaldosteronism subtypes predictive model using ensemble learning
Karashima, S., Kawakami, M., Nambo, H., Kometani, M., Kurihara, I., Ichijo, T., Katabami, T., Tsuiki, M., Wada, N., Oki, K., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-29653-2 · Cited by 12
“Patients with suspected autonomous cortisol secretion (serum cortisol > 1.8 µg/dL after 1 mg dexamethasone) were excluded 41 .”
BackgroundInfluentialDifferential Diagnosis of Cushing’s Syndrome
Javorsky, B. R., Carroll, T. B., & Findling, J. W. (2011) · Endocrine updates · doi:10.1007/978-1-4614-0011-0_7 · Cited by 10
“any type of exogenous corticosteroid treatment [7].”
BackgroundSelf-citationSubclinical Cushing's syndrome
Tsinberg, M., Liu, C., & Duh, Q. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23143 · Cited by 9
“Several tests of the HPA axis are available and have been evaluated in different studies [9,10].”
MethodCushing's disease in a patient with steroid 21-hydroxylase deficiency
Haase, M., Schott, M., Kaminsky, E., Lüdecke, D. K., Saeger, W., Fritzen, R., Schinner, S., Scherbaum, W. A., & Willenberg, H. S. (2011) · Endocrine Journal · doi:10.1507/endocrj.k11e-097 · Cited by 9
“her urine was elevated three times: 5161 nmol/24h (187 μg/24h), 7066 nmol/24h (256 μg/24h), and 9108 nmol/24h (330 μg/24h) with a normal endogenous creatinine clearance of 96 mL/min confirming the diagnosis of hypercortisolism [9].”
BackgroundMass spectrometry for the endocrine clinic – much to digest
Monaghan, P. J., Keevil, B. G., & Trainer, P. J. (2013) · Clinical Endocrinology · doi:10.1111/cen.12125 · Cited by 8
Nouvel, M., Rabilloud, M., Raverot, V., Subtil, F., Vouillarmet, J., Thivolet, C. H., Jouanneau, E., Borson‐Chazot, F., PUGEAT, M. M., & Raverot, G. (2015) · Annales d Endocrinologie · doi:10.1016/j.ando.2015.11.001 · Cited by 10
“For the diagnosis of CD, the Endocrine Society Clinical ractice guidelines recommended one of the following tests: t least two 24-hour urinary free cortisol tests, 1-mg overnight examethasone suppression test, or two measurements of late alivary cortisol [3,4].”
BackgroundMethodThe eye and the skin in endocrine metabolic diseases
Urrets‐Zavalía, J. A., Espósito, E., Garay, I. S., Monti, R., Ruiz-Lascano, A., Correa, L. J., Serra, H. M., & Grzybowski, A. E. (2015) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2015.12.001 · Cited by 9
SUBCLINICAL HYPERCORTISOLISM IN CENTRAL SEROUS CHORIORETINOPATHY
Appa, S. N. (2014) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000036 · Cited by 9
“European epidemiologic studies have estimated the incidence to be approximately 2 to 3 cases per million, and women are affected more frequently than men.(3) Several authors have reported the coexistence of endogenous Cushing syndrome and CSC.”
BackgroundCase 40-2011: A 52-Year-Old Man with Weakness, Infections, and Enlarged Adrenal Glands
Tritos, N. A., Schaefer, P. W., & Stein, T. D. (2011) · New England Journal of Medicine · doi:10.1056/nejmcpc1100919 · Cited by 9
Villéon, B. D. L., Bonnet, S., Gouya, H., Groussin, L., Tenenbaum, F., Gaujoux, S., & Dousset, B. E. (2016) · Surgery · doi:10.1016/j.surg.2016.03.008 · Cited by 9
Faje, A. T., Tritos, N. A., Swearingen, B., & Klibanski, A. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53486-6.00044-2 · Cited by 10
Poonuru, S., Findling, J. W., & Shaker, J. L. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3712-6 · Cited by 9
“The diagnosis of CS was made based on evidence-based guidelines [9].”
MethodSelf-citationCushing’s syndrome in infancy due to ectopic ACTH secretion by a sacro-coccygeal teratoma
Rydzewska, M., Krawczuk‐Rybak, M., Zajkowska, A., Jurczuk, N., Polnik, D., Szalecki, M., Moszczyńska, E., Savage, M. O., & Bossowski, A. T. (2017) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2016-0339 · Cited by 9
Self-citationFunktionsdiagnostik in der Endokrinologie
Auernhammer, C. J., & Reincke, M. (2017) · Der Internist · doi:10.1007/s00108-017-0360-7 · Cited by 11
Gu, Y., Gu, W., Dou, J., Lv, Z., Li, J., Zhang, S., Yang, G., Guo, Q., Ba, J., Zang, L., et al. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i8.961 · Cited by 11
Investigating cortisol excess or deficiency: a practical approach
Hanna, F., Issa, B. G., Kevil, B., & Fryer, A. A. (2019) · BMJ · doi:10.1136/bmj.l6039 · Cited by 11
Zhang, Y., Guo, X., Wang, L., et al. (2020) · International Journal of Endocrinology · doi:10.1155/2020/4056591 · Cited by 9
Avascular femoral necrosis as part of Cushing syndrome presentation: a case report
Salazar, D. A., Esteves, C., Ferreira, M. J., et al. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02882-7 · Cited by 9
“Nonetheless, typical signs and symptoms of CS are generally well recognized [13].”
BackgroundHypertension in Cushing’s Syndrome
Ceccato, F., Barbot, M., Scaroni, C. M., & Boscaro, M. (2020) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-030-45562-0_8 · Cited by 9
Herman-Bonert, V. S. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6109-0.00065-4 · Cited by 9
Sardana, K., Muddebihal, A., Sehrawat, M., Bansal, P., & Khurana, A. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2299400 · Cited by 13
“It is pertinent to understand that the investigative panel (Table 3) [42,43,45,48,62–75] is dependent on the clinical presentation and exhaustive panels are inadvisable ,as they are costly and may not help consitently in the etiological diagnosis [76].”
BackgroundInfluentialHair cortisol and changes in cortisol dynamics in chronic kidney disease
Boswell, L., Vega‐Beyhart, A., Blasco, M., Quintana, L. F., Rodríguez, G., Díaz-Catalán, D., Vilardell, C., Claro, M. I., Mora, M., Amor, A. J., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1282564 · Cited by 9
“HPA axis evaluation is complex, and standard biochemical tests have limitations and methodologic dif fi culties (7).”
BackgroundIncreased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas
Sousa, S. M. C. D., McCormack, A. I., Orsmond, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae268 · Cited by 8
Mangone, A., Favero, V., Prete, A., Elhassan, Y., Asia, M. F., Hardy, R., Mantovani, G., Chiodini, I., & Ronchi, C. L. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02426-y · Cited by 8
Colao, A., Scaroni, C. M., Mezősi, E., Saiegh, L., Puig‐Domingo, M., Marques, P., & Deutschbein, T. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae073 · Cited by 11
Durmuş, E. T., Kefeli, M., Mete, Ö., Çalışkan, S., Aslan, K., Onar, M. A., Çolak, R., Durmuş, B., Çokluk, C., & Atmaca, A. A. (2024) · Endocrine Pathology · doi:10.1007/s12022-024-09819-y · Cited by 9
“Standard biochemical screening was performed according to the guidelines [20], including increased excretion of 24-h urinary free cortisol (UFC) (at least two measurements), abnormal circadian rhythm with late-night salivary cortisol (at least two measurements), and impaired glucocorticoid feedback…”
MethodLiu, M., Zhao, W., Zhang, W., Tian, Z., Zhang, Z., Lou, Y., Zhang, Z., Yang, F., Zhu, D., & Li, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1373101 · Cited by 9
How to manage Cushing's disease after failed primary pituitary surgery
Agrawal, N., Urwyler, S. A., Mehta, S., Karavitaki, N., & Feelders, R. A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae110 · Cited by 8
Discordance between adrenal vein sampling and imaging: the role of unilateral cortisol excess
Grundy, M., Leung, A. A. C., Hyrcza, M. D., Pasieka, J. L., Chan, D. S., Przybojewski, S. J., So, B., Orton, D. J., Harvey, A. M., & Kline, G. A. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf019 · Cited by 11
“39,41 However, the coexistence of even subtle autonomous cortisol excess may jeopardize the reliability of AVS when using cortisol for interpretation, which can lead to either treatment inertia or worse, inappropriate contralateral adrenalectomy.”
68Ga-DOTATOC PET/CT in the Localization of Pituitary Tumors in Cushing’s Disease
Kim, K., Kim, D. W., Lee, M., Park, Y. W., Ahn, S. S., Moon, J. H., Kim, E. H., Kim, S. H., Ku, C. R., & Lee, E. J. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2249 · Cited by 10
“An 8:00 AM plasma cortisol concentration higher than 1.8 µg/dL, after 1 mg dexamethasone had been administered at midnight, was considered a positive result in the overnight dexamethasone suppression test (ON DST) [4,8].”
InfluentialSandooja, R., Saini, J., Taveras, E. F., Garcia, R. G., Zhang, C. D., Fell, V. M., Peersen, A. F., Achenbach, S. J., Atkinson, E. J., Gompel, J. J. V., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf092 · Cited by 9
Nowak, E., Viëtor, C. L., Feelders, R. A., Hofland, J., Araujo-Castro, M., Ojeda, C. M., Corrales, E. P., Salama, B., Bancos, I., Sandooja, R., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00302-x · Cited by 9
DIFFERENT SURGICAL OPTIONS IN CUSHING’S DISEASE
Valea, A., Ghervan, C., Carşote, M., Albu, S. E., & Georgescu, C. E. (2016) · Journal of Surgical Sciences · doi:10.33695/jss.v3i1.46 · Cited by 8
Aberrant DNA methylation of synaptophysin is involved in adrenal cortisol-producing adenoma
Zhong, J., Cui, R., Lin, X., Xu, F., Zhu, T., Li, F., Wu, F., Zhou, E., Lu, Y., & Yuan, L. (2019) · Aging · doi:10.18632/aging.102119 · Cited by 9
Muraca, E., Oltolini, A., Binda, A., Pizzi, M., Ciardullo, S., Manzoni, G., Zerbini, F., Bianconi, E., Cannistraci, R., Perra, S., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab161 · Cited by 10
Carton, T., Mathieu, E., Wolff, F., Bouziotis, J., Corvilain, B., & Driessens, N. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.255 · Cited by 10
Diurnal salivary cortisol profiles in patients with Cushing's syndrome
Braun, L. T., Vogel, F., Zopp, S., Rubinstein, G., Schilbach, K., Künzel, H., Beuschlein, F., & Reincke, M. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1719-5381 · Cited by 8
“UFC: urinary free cortisol).”
BackgroundMethodInfluentialSalivary Steroid Collection in Children Under Conditions Replicating Home Sampling
Tonge, J. J., Keevil, B. G., Craig, J. N., Whitaker, M. J., Ross, R. J. M., & Elder, C. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac419 · Cited by 9
Hamblin, R., Fountas, A., Levy, M. J., & Karavitaki, N. (2022) · Pituitary · doi:10.1007/s11102-022-01290-4 · Cited by 8
“Investigation for Cushing’s disease, in the absence of a high index of clinical suspicion or pre-test probability, invariably increases the risk of false-positives and potential for unwarranted investigation and anxiety [34, 35].”
BackgroundBotelho, M. L. A. D. A., Nishi, M. Y., Ribeiro, K. B., & Zerbini, M. C. N. (2023) · Endocrine Pathology · doi:10.1007/s12022-023-09761-5 · Cited by 9
Development of diagnostic algorithm for Cushing’s syndrome: a tertiary centre experience
Efthymiadis, A., Loo, H., Shine, B.-K., James, T. J., Keevil, B. G., Tomlinson, J., Pal, A., & Pofi, R. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02354-x · Cited by 11
“For patients with adrenal incidentalomas being evaluated for hypercortisolism, ODST is recommended as a first test, with consideration of additional UFC and/or LNSC measurements [9, 11].”
MethodA dilute and shoot method for urinary free cortisol analysis by LC-MS/MS
Shen, Y., Luo, X., Guan, Q., & Cheng, L. (2024) · Journal of Chromatography B · doi:10.1016/j.jchromb.2024.124127 · Cited by 8
Pattern of adrenal morphology and function in patients with acromegaly
Παππά, Θ., Papanastasiou, L., Koutmos, S., Tsiavos, V., Roussaki, P., Zilos, A., Ragkou, D., Kaltsas, G., & Piaditis, G. P. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02580.x · Cited by 9
Mendoza, C. F., Ontiveros, P., Xibillé, D. X., & Rivera, M. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0031-4 · Cited by 8
“pituitary ACTH-producing tumor [14, 15]; however, it has been described that in up to 20 % of patients the site of ectopic ACTH secretion cannot be identified.”
BackgroundWang, Y., Chuang, M., Chuang, T., Huang, K.-Y., Lyu, S., Huang, C., & Lee, C. (2014) · International Journal of Endocrinology · doi:10.1155/2014/138653 · Cited by 9
Peptide Hormones as Tumor Markers in Clinical Practice
Sun, Q., & Zhao, Z. (2017) · The Enzymes · doi:10.1016/bs.enz.2017.09.001 · Cited by 8
Wijewickrama, P. S. A., Ratnasamy, V., Somasundaram, N. P., Sumanatilleke, M., & Ambawatte, S. B. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00701-0 · Cited by 8
“However, the presence of more discriminatory features, including purple striae, plethora, proximal myopathy, easy bruising, thin skin and unexplained osteoporosis should prompt the clinician to evaluate further with initial investigations including urinary free cortisol, late night salivary cortisol, 1 mg overnight de…”
BackgroundShi, X., Du, T., Zhu, D. Y., Ma, D., Dong, K., Peng, X., Huang, J., Lei, T., Yu, X., Chen, J., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02891-y · Cited by 8
Spontaneous bone infarction of the distal femur in a patient with Cushing's disease: a case report
van Houten, P., de Rooy, J., van der Geest, I. C. M., Netea-Maier, R. T., & van de Ven, A. C. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.100756 · Cited by 9
Development of 68 Ga DOTA-CRH for PET/CT Imaging of ACTH-Dependent Cushing's Disease: Initial Study
Shukla, J., Vatsa, R., Walia, R., Chhabra, A., Rana, N., Singh, H., Kumar, R., & Mittal, B. R. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.4686 · Cited by 10
Voulgaris, N., Tyfoxylou, E., Vlachou, S., Kyriazi, E., Gravvanis, C., Kapsali, C., Markou, Α., Papanastasiou, L., Gryparis, A., Kassi, E. N., et al. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1507-5226 · Cited by 9
“Therefore, using them as complementary tests it should be an ideal diagnostic PA process, similar to that used in Cushing syndrome [29].”
MethodFajardo, C., Villar, R., Gómez‐Ansón, B., Brea, B., Mosqueira, A. J., Mollá, E., Enseñat, J., Riesgo, P., Arboniés, J. C., & Hernando, O. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.10.005 · Cited by 14
Moreno-Moreno, P., Ibáñez‐Costa, A., Venegas-Moreno, E. M., Fuentes-Fayos, A. C., Alhambra-Expósito, M. R., Fajardo, C., García‐Martínez, A., Dios, E., Vazquez-Borrego, M. C., Remón-Ruiz, P., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac172 · Cited by 9
Treatment of Primary Pigmented Nodular Adrenocortical Disease
Gang, X., Wang, G., Liu, X., Zhang, S., & Guo, Y. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1948-6990 · Cited by 14
“The dexamethasone-CRH test or the midnight serum cortisol test can be used as subsequent evaluation to establish the cause of CS in patients with concordantly positive results from two different initial tests [34].”
MethodCushing’s syndrome in women: age-related differences in etiology and clinical picture
Akirov, A., Dery, L., Fleseriu, M., Rudman, Y., Shimon, I., Manisterski, Y., Aviran-Barak, N., Nadler, V., Alboim, S., Shochat, T., et al. (2022) · Pituitary · doi:10.1007/s11102-022-01292-2 · Cited by 12
“The computerized database of Maccabi Healthcare Services was screened for all individuals with 24-h urinary free cortisol test (UFC) levels that were at least two times above the upper normal range (UFC > 2 × ULN) and a diagnosis of overt CS established by an expert endocrinologist with recorded biochemical data compa…”
MethodCarcinoid tumors outside the abdomen
Koehler, K., & Iams, W. T. (2022) · Cancer Medicine · doi:10.1002/cam4.5564 · Cited by 8
Wexler, T., & Page‐Wilson, G. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15660 · Cited by 13
Intraoperative Predictor of Remission in Cushing Disease
Zachariah, M. A., Cua, S., Muhlestein, W. E., Otto, B. A., Carrau, R. L., Kirschner, L. S., Ghalib, L. M., Lonser, R. R., Hardesty, D. A., & Prevedello, D. M. (2022) · Operative Neurosurgery · doi:10.1227/ons.0000000000000560 · Cited by 9
Sulu, C., Koca, O., Icli, T. B., Öz, A., Kargın, O. A., Durcan, E., Şahin, S., Arslan, S., Turan, Ş., Kadıoğlu, P., et al. (2023) · Neuroradiology · doi:10.1007/s00234-023-03156-3 · Cited by 11
“The diagnosis, treatment, and follow-up of CD and adrenal-dependent CS were based on internationally agreed guidelines [30-33].”
BackgroundMethodCirculating myomiRNAs as biomarkers in patients with Cushing’s syndrome
Pivonello, C., Patalano, R., Simeoli, C., Montò, T., Negri, M., Amatrudo, F., Paola, N. D., Larocca, A., Crescenzo, E. M., Pirchio, R., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02184-3 · Cited by 9
“The diagnosis of CS was performed with the presence of two of the following criteria, according to the Endocrine Society Guidelines [32]: (1) abnormal (> upper limit of normal (ULN) range) UFC levels in at least two different samples; (2) abnormal (> 1.8 µg/dl) cortisol response to the overnight…”
MethodInfluentialReimondo, G., Allasino, B., Coletta, M., Pia, A. R., Peraga, G., Zaggia, B., Massaglia, C., Paccotti, P., & Terzolo, M. (2015) · International Journal of Endocrinology · doi:10.1155/2015/674734 · Cited by 8
Adrenal incidentalomas and subclinical Cushing’s syndrome
Abdelmannan, D. K., & Aron, D. C. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9141-5 · Cited by 8
“Treatment of patients with moderate to severe Cushing’s syndrome clearly reduces mortality and morbidity [ 3 ].”
BackgroundInfluentialSyndrome de Cushing et grossesse : à propos d’un cas de corticosurrénalome
Homer, L., Viatge, M., Gayet, F.-X., Laurent, Y., & Kerlan, V. (2012) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2011.07.053 · Cited by 9
Incidentalomas suprarrenales: experiencia clínica en los hospitales de Castilla-La Mancha
Lamas, C., Palma, M., Martín, D., de Frutos, V. Á., López, M., & Marco, A. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)72708-1 · Cited by 8
Shiwa, T., Oki, K., Yamane, K., Yoneda, M., Awaya, T., Nakanishi, S., & Kohno, N. (2013) · Clinical Endocrinology · doi:10.1111/cen.12197 · Cited by 9
Republished: Clinicopathological correlates of adrenal Cushing's syndrome
Duan, K., Hernandez, K., & Mete, Ö. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-202612rep · Cited by 9
Medical Treatment of Cushing’s Disease
Hopkins, S., & Fleseriu, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804340-0.00007-3 · Cited by 9
Pseudo-Cushing - A Clinical Challenge?
Giraldi, F. P., & Ambrogio, A. G. (2016) · Frontiers of hormone research · doi:10.1159/000443859 · Cited by 10
Zhou, W., Wu, L., Xie, J., Su, T., Jiang, L., Jiang, Y., Cao, Y., Liu, J., Ning, G., & Wang, W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162606 · Cited by 8
“The diagnosis of ACTH-independent Cushing’s syndrome was based on the results of hormonal investigations [18], whereas the pathological examination of the adrenal tissues confirmed the ACA diagnosis.”
MethodEspiard, S., Benomar, K., Loyer, C., Vahé, C., & Vantyghem, M. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.08.002 · Cited by 12
Trauma-induced adiposis dolorosa (Dercum’s disease)
Hao, D., Olugbodi, A., Udechukwu, N. S., & Donato, A. A. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-223869 · Cited by 8
Goyal, A., Gupta, U., Kandasamy, D., & Khadgawat, R. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_581_18 · Cited by 8
Laboratory tests commonly used in complementary and alternative medicine: a review of the evidence
Jones, S. L., Campbell, B. K., & Hart, T. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563218824622 · Cited by 8
Roerink, S. H. P. P., Cocks, M. S., Wagenmakers, M. A. E. M., Rodighiero, R. P., Strauss, J. A., Shepherd, S. O., Plantinga, T. S., Thijssen, D. H. J., Hopman, M. T. E., Pereira, A. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz286 · Cited by 12
“Remission was defined as suppression of plasma cortisol to 50 nmol/L or less after 1 mg dexamethasone overnight and absence of clinical signs and symptoms of active hypercortisolism, documented no longer than 1 year before inclusion (7).”
MethodMuraca, E., Ciardullo, S., Perra, S., Zerbini, F., Oltolini, A., Cannistraci, R., Bianconi, E., Villa, M., Pizzi, M., Pizzi, P., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3389 · Cited by 9
“Cushing's syndrome (CS) is, in the majority of cases, due to medically prescribed corticosteroids and less frequently to independent adrenal, pituitary or ectopic overproduction.(1) From a metabolic point of view, CS is characterized by central obesity, altered glucose metabolism or overt type 2 diabetes mellitus (T2D…”
BackgroundMethodResultInfluentialRahmani, F., Mahdavi, M., Edraki, K., & Valizadeh, M. (2020) · HORMONES · doi:10.1007/s42000-020-00240-8 · Cited by 8
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.